Literature DB >> 18000386

Genetics and epigenetics of 1q rearrangements in hematological malignancies.

A Fournier1, A Florin, C Lefebvre, F Solly, D Leroux, M B Callanan.   

Abstract

Recently, we and others have described a novel class of chromosome aberrations that involves constitutive heterochromatin on human chromosome 1 (cytogenetic band 1q12). These anomalies are particularly frequent in B cell non-Hodgkins lymphoma (NHL) and multiple myeloma (MM) and, remarkably, almost invariably involve partial or total gain of chromosome 1q (including 1q12 heterochromatin) and the formation of novel heterochromatin/euchromatin junctions. This review discusses the pathological significance of these anomalies in light of i) recent integrated gene expression and array comparative genomic hybridisation (aCGH) profiling in MM and ii) increasing evidence of a key role for heterochromatin in the control of normal and pathological gene silencing. Copyright (c) 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18000386     DOI: 10.1159/000108316

Source DB:  PubMed          Journal:  Cytogenet Genome Res        ISSN: 1424-8581            Impact factor:   1.636


  8 in total

1.  Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma.

Authors:  Jeffrey R Sawyer; Erming Tian; Christoph J Heuck; Donald J Johann; Joshua Epstein; Charles M Swanson; Janet L Lukacs; Regina Lichti Binz; Marian Johnson; Gael Sammartino; Maurizio Zangari; Faith E Davies; Frits van Rhee; Gareth J Morgan; Bart Barlogie
Journal:  Blood       Date:  2015-05-05       Impact factor: 22.113

2.  Two rare cases of acute myeloid leukemia with t(8;16)(p11.2;p13.3) and 1q duplication: case presentation and literature review.

Authors:  Meng Liu; Yuan Ren; Xianfu Wang; Xianglan Lu; Ming Li; Young Mi Kim; Shibo Li; Lijun Zhang
Journal:  Mol Cytogenet       Date:  2020-08-25       Impact factor: 2.009

3.  Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease.

Authors:  Jeffrey R Sawyer; Erming Tian; Christoph J Heuck; Joshua Epstein; Donald J Johann; Charles M Swanson; Janet L Lukacs; Marian Johnson; Regina Binz; Angela Boast; Gael Sammartino; Saad Usmani; Maurizio Zangari; Sarah Waheed; Frits van Rhee; Bart Barlogie
Journal:  Blood       Date:  2014-02-04       Impact factor: 22.113

4.  1q12 chromosome translocations form aberrant heterochromatic foci associated with changes in nuclear architecture and gene expression in B cell lymphoma.

Authors:  Alexandra Fournier; Anne McLeer-Florin; Christine Lefebvre; Samuel Duley; Leila Barki; Juliana Ribeyron; Kassambara Alboukadel; Sieme Hamaidia; Aurélie Granjon; Rémy Gressin; Alicia Lajmanovich; Thierry Bonnefoix; Stéphanie Chauvelier; Alexandra Debernardi; Sophie Rousseaux; Florence de Fraipont; Martin Figeac; Jean-Pierre Kerckaert; John De Vos; Yves Usson; Katia Delaval; Alexei Grichine; Claire Vourc'h; Saadi Khochbin; Robert Feil; Dominique Leroux; Mary B Callanan
Journal:  EMBO Mol Med       Date:  2010-05       Impact factor: 12.137

Review 5.  An emerging role for epigenetic dysregulation in arsenic toxicity and carcinogenesis.

Authors:  Xuefeng Ren; Cliona M McHale; Christine F Skibola; Allan H Smith; Martyn T Smith; Luoping Zhang
Journal:  Environ Health Perspect       Date:  2010-08-02       Impact factor: 9.031

6.  Remodeling and destabilization of chromosome 1 pericentromeric heterochromatin by SSX proteins.

Authors:  Sofie Traynor; Niels Erik Møllegaard; Mikkel G Jørgensen; Nadine H Brückmann; Christina B Pedersen; Mikkel G Terp; Simone Johansen; Jerome Dejardin; Henrik J Ditzel; Morten F Gjerstorff
Journal:  Nucleic Acids Res       Date:  2019-07-26       Impact factor: 16.971

7.  Associations Between Amplification (1q) and Prior Cancer in a Real-World De Novo Myeloma Cohort.

Authors:  Elizabeth B Lamont; Andrew J Yee; Stuart L Goldberg; David S Siegel; Andrew D Norden
Journal:  JNCI Cancer Spectr       Date:  2021-01-04

Review 8.  Multiple Myeloma With Amplification of Chr1q: Therapeutic Opportunity and Challenges.

Authors:  Romanos Sklavenitis-Pistofidis; Gad Getz; Irene Ghobrial; Maria Papaioannou
Journal:  Front Oncol       Date:  2022-07-14       Impact factor: 5.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.